Latest Patents

Patents imply intellectual property and it has a $ value that can be associated depending on the field and type of patent that is allocated. Patents also increase the enterprise value of the company and help prevent copy-cats from copying the idea without having royalt payments or licencing deals. We like it when companies get patents awarded!. To protect IP companies aggressively file provisional patents even before they have a working product. The below table provides a way to look at what has been done by companies and use this as a factor to make investment decisions.

     
Title Filing Date Publication Date Grant Date
Neurotrophic tyrosine receptor kinase (ntrk) degrading compounds 2022-9-29 2023-4-06
Selected compounds for targeted degradation of BRD9 2022-9-09 2023-3-17
Selected compounds for targeted degradation of brd9 2022-9-09 2023-3-09
Compounds for targeted degradation of brd9 2022-9-01 2023-3-02
Compounds for targeting degradation of irak4 proteins 2022-7-07 2023-1-12
Compounds for targeting degradation of irak4 proteins 2022-7-07 2023-1-12
Isoindolinone and indazole compounds for epidermal growth factor receptor (egfr … 2022-6-17 2022-7-08
Isoindolinone and indazole compounds for the degradation of egfr 2022-6-17 2023-4-13
Therapeutics for the degradation of mutant braf 2022-6-08 2023-2-23
Egfr degraders to treat cancer metastasis to the brain or cns 2022-5-26 2022-12-01
Compounds for targeting degradation of bruton's tyrosine kinase 2022-5-05 2022-11-10
Tricyclic degraders of ikaros and aiolos 2022-4-18 2023-3-16
Tunable endogenous protein degradation 2022-1-20 2022-5-05
Dihydrobenzimidazolones for medical treatment 2022-1-14 2022-9-15
Spirocyclic degronimers for target protein degradation 2021-11-11 2023-3-30
Tricyclic ligands for degradation of ikzf2 or ikzf4 2021-10-14 2022-4-21
Tricyclic compounds to degrade neosubstrates for medical therapy 2021-10-14 2022-4-21
Tricyclic heterobifunctional compounds for degradation of targeted proteins 2021-10-14 2022-4-21
Heterocyclic compounds for medical treatment 2021-9-02 2023-1-19
Advantageous therapies for disorders mediated by Ikaros or Aiolos 2021-8-06 2023-4-13
ADVANTAGE THERAPIES FOR DISORDERS MEDIATED BY IKAROS OR AIOLOS 2021-8-06 2022-11-02
Advantageous therapies for disorders mediated by ikaros or aiolos 2021-8-06 2022-6-01
Compounds for targeted degradation of ret 2021-8-05 2022-2-10
Targeted protein degradation 2021-6-18 2022-11-24
Heterobifunctional compounds as degraders of braf 2021-6-18 2021-12-23
Braf degraders 2021-6-18 2021-12-23
BRAF DEGRADERS 2021-6-18 2022-9-28
COMPOUNDS FOR THE TARGETED DEGRADATION OF BRD9 2021-3-05 2022-6-08
Compounds for the degradation of brd9 or mth1 2021-3-04 2021-7-01
Heterocyclic degronimers for target protein degradation 2021-2-01 2023-1-19
ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR EGFR DEGRADATION 2020-12-21 2022-3-23
Substituted piperidine degronimers for target protein degradation 2020-12-14 2022-10-06
C3-carbon linked glutarimide degronimers for target protein degradation 2020-11-30 2022-10-06
Compounds 2020-11-25 2021-3-18
Spirocyclic compounds 2020-11-24 2023-4-11 2023-4-11
Spirocyclic compounds 2020-11-24 2021-3-11
Bifunctional compounds for the treatment of cancer 2020-10-28 2022-9-07
Bifunctional compounds 2020-10-26 2022-6-07
Spirocyclic compounds 2020-10-16 2021-2-04
Cereblon binders for the degradation of ikaros 2020-9-24 2021-1-14
Bifunctional molecules that degrade egfr 2020-8-04 2020-11-19
Bifunctional inhibitors with egfr having a e3 ubiquitin ligase moiety 2020-6-16 2020-10-01
Degraders and degrons for targeted protein degradation 2020-5-14 2022-8-11
Glutarimides for medical treatment 2020-3-04 2020-7-02
Dihydroquinolinones for medical treatment 2020-3-04 2020-7-02
N/o-linked degrons and degronimers for protein degradation 2019-12-19 2020-5-07
Substituted isoindole allosteric egfr inhibitors,pharmaceutical compositions … 2019-11-28 2022-10-01
HSPC-sparing treatments for RB-positive abnormal cellular proliferation 2018-11-01 2021-2-23 2021-2-23
Compounds 2018-6-01 2018-12-06
Regulating chimeric antigen receptors 2018-2-08 2022-4-26 2022-4-26
Tunable endogenous protein degradation with heterobifunctional compounds 2018-2-08 2019-12-12
2-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compounds 2017-12-21 2018-6-28
Bromodomain targeting degronimers for target protein degradation 2017-5-10 2017-11-16
Composés de dégradation de kinase du récepteur de la tyrosine neurotrophique ( … 2022-9-29 2023-4-06